Welcome to our dedicated page for Eyepoint Pharmac news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on Eyepoint Pharmac stock.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical innovator advancing sustained-release therapies for retinal diseases through its proprietary Durasert E technology. This page provides investors and industry professionals with a comprehensive repository of official company news, including press releases, clinical trial updates, and strategic developments.
Access timely updates on EYPT’s progress in ocular drug delivery, including regulatory milestones, partnership announcements, and pipeline advancements. Our curated collection ensures you stay informed about critical developments in treatments for wet AMD, diabetic macular edema, and other retinal conditions.
Key updates include progress on DURAVYU™ clinical trials, licensing agreements, financial disclosures, and scientific innovations. All content is sourced directly from company communications to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to EyePoint’s latest developments. Check back regularly for authoritative updates on one of ophthalmology’s most promising sustained-release therapy developers.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q4 and full-year 2024 financial results, highlighting significant progress in its DURAVYU clinical trials. The LUGANO Phase 3 trial for wet AMD is over 50% enrolled, with both LUGANO and LUCIA trials expected to complete enrollment in H2 2025 and topline data in 2026.
The company reported positive Phase 2 VERONA trial results for DURAVYU in DME, meeting primary and secondary endpoints. Q4 2024 financial results showed total net revenue of $11.6M (down from $14.0M in Q4 2023), with a net loss of $41.4M ($0.64 per share).
Full-year 2024 results included total net revenue of $43.3M (compared to $46.0M in 2023) and a net loss of $130.9M ($2.32 per share). The company maintains a strong financial position with $371M in cash and investments as of December 31, 2024, providing runway into 2027.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a developer of innovative therapeutics for serious retinal diseases, has announced its participation in two major upcoming investor conferences in March 2025.
The company will deliver a corporate presentation at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 4:20 p.m. ET. Additionally, EyePoint will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 3:00 p.m. ET.
Investors can access live webcasts and archived replays of both presentations through the Investors section of EyePoint's website at www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has scheduled its fourth quarter and full-year 2024 financial results announcement for March 5, 2025. The company, which focuses on developing innovative therapeutics for serious retinal diseases, will host a conference call and webcast at 8:30 a.m. ET.
Investors and interested parties can access the live conference call through a registration link, while a live audio webcast will be available through the Investors section of EyePoint's website. A replay of the webcast will be accessible on the corporate website after the call concludes.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that its President and CEO, Jay S. Duker, M.D., will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th, 2025, at 9:10 a.m. ET.
During the presentation, EyePoint will provide an enrollment update for its ongoing DURAVYU™ Phase 3 pivotal program in wet age-related macular degeneration (wet AMD). Additionally, the company will share additional subgroup analyses from the Phase 2 VERONA clinical trial of DURAVYU in diabetic macular edema (DME).
The presentation will be available via live webcast with an archived replay accessible through the Investors section of EyePoint's website at www.eyepointpharma.com. EyePoint is focused on developing and commercializing innovative therapeutics for patients with serious retinal diseases.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to two new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee on February 14, 2025, include options to purchase up to 21,000 shares of common stock at an exercise price of $6.50 per share.
The options have a ten-year term and follow a four-year vesting schedule, with 25% vesting on the first anniversary and the remaining shares vesting in equal monthly installments over the following three years. Vesting is contingent upon continued employment with EyePoint Pharmaceuticals.
EyePoint Pharmaceuticals announced positive six-month results from its Phase 2 VERONA clinical trial of DURAVYU™ for Diabetic Macular Edema (DME). The trial met its primary endpoint with both DURAVYU doses (1.34mg and 2.7mg) showing extended time to first supplemental injection versus aflibercept control.
The DURAVYU 2.7mg dose demonstrated significant improvements, including: +7.1 letter BCVA gain, 76-micron CST reduction at week 24, and 73% supplement-free rate compared to 50% for aflibercept. The treatment showed immediate bioavailability and maintained efficacy throughout the six-month trial with no DURAVYU-related serious adverse events.
The company plans to initiate a Phase 3 non-inferiority pivotal program by the end of 2025, following FDA discussions in Q2. The VERONA trial included 27 patients and evaluated safety, visual acuity changes, and central subfield thickness as key endpoints.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. Jay S. Duker, M.D., the company's President and CEO, will engage in a fireside chat scheduled for Thursday, February 6, 2025, at 9:30 a.m. ET.
Interested parties can access the webcast and subsequent replay through the Investors section of EyePoint's website at www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to four new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee on January 15, 2025, allow the purchase of up to 30,300 shares of common stock at an exercise price of $7.69 per share, matching the closing price on the grant date.
The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first anniversary, with the remaining shares vesting in equal monthly installments over the following three years. Vesting is contingent upon continued employment with EyePoint.
EyePoint Pharmaceuticals (NASDAQ: EYPT) provided updates on its lead product candidate, DURAVYU™, and key milestones for 2025. The company reported strong enrollment in its Phase 3 wet AMD clinical trials, with LUGANO being one-third enrolled and LUCIA ahead of schedule. Both trials are expected to complete enrollment in H2 2025, with topline data in 2026.
The company highlighted positive interim results from the Phase 2 VERONA trial in DME, with full data expected in Q1 2025. DURAVYU demonstrated meaningful improvements in patients with active DME, showing CST improvement of 68.1 microns and BCVA gain of +8.9 letters vs. baseline.
Notable corporate updates include the appointment of Dr. Reginald J. Sanders to the Board and the opening of a new 40,000+ square-foot manufacturing facility in Northbridge, MA. The company reported approximately $370 million in cash and investments as of December 31, 2024, with runway extending into 2027.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has appointed Dr. Reginald J. Sanders, a prominent retina specialist, to its Board of Directors. Dr. Sanders, the most recent President of the American Society of Retina Specialists, brings extensive clinical and business development experience in retinal diseases.
The appointment comes at a important time as EyePoint advances its global phase 3 pivotal trials for wet AMD and following positive interim data from its Phase 2 trial in diabetic macular edema. Dr. Sanders has significant experience as a principal investigator, including work on Lucentis® for wet AMD treatment, and has published over 50 papers. He currently serves as a board member of Prism Vision Group and is affiliated with the Retina Group of Washington, which he helped build into the largest retinal specialist practice in the United States.
FAQ
What is the current stock price of Eyepoint Pharmac (EYPT)?
What is the market cap of Eyepoint Pharmac (EYPT)?
